Top Page
Affluent Partners Holdings
(1466)
Affluent Partners Holdings (1466) vs. iShares MSCI Hong Kong ETF (EWH)
Affluent Partners Holdings Business Overview & Revenue Model
Affluent Partners Holdings Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 135.56M | 53.68M | 135.56M | 86.88M | 62.65M | 43.32M |
| Gross Profit | 41.99M | 18.10M | 41.99M | 7.83M | 10.99M | -8.62M |
| EBITDA | 6.26M | -6.32M | 6.26M | 11.13M | -9.73M | -45.45M |
| Net Income | -316.00K | -7.45M | -316.00K | 8.73M | -15.46M | -51.78M |
Balance Sheet | ||||||
| Total Assets | 290.17M | 196.80M | 290.17M | 99.85M | 82.11M | 91.77M |
| Cash, Cash Equivalents and Short-Term Investments | 47.77M | 37.88M | 47.77M | 41.26M | 23.59M | 24.42M |
| Total Debt | 99.93M | 51.19M | 99.93M | 2.76M | 31.84M | 31.56M |
| Total Liabilities | 134.30M | 84.01M | 134.30M | 21.51M | 46.24M | 45.82M |
| Stockholders Equity | 139.28M | 96.31M | 139.28M | 78.34M | 35.87M | 45.95M |
Cash Flow | ||||||
| Free Cash Flow | -32.20M | -6.64M | -32.97M | -21.55M | 1.06M | -16.21M |
| Operating Cash Flow | -29.75M | -6.46M | -30.53M | -21.52M | 1.11M | -16.18M |
| Investing Cash Flow | -846.00K | 4.74M | -846.00K | 35.30M | -60.00K | 138.00K |
| Financing Cash Flow | 41.41M | 819.00K | 41.41M | 3.70M | -1.72M | 6.77M |
Affluent Partners Holdings Technical Analysis
Affluent Partners Holdings Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$454.65M | 5.00 | 11.34% | 6.00% | 14.52% | 15.74% | |
70 Outperform | HK$1.77B | 9.75 | 10.00% | 9.67% | -9.00% | -21.55% | |
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
55 Neutral | $612.16M | -15.44 | -1.15% | ― | -41.44% | -209.76% | |
52 Neutral | HK$484.77M | 49.52 | 7.10% | ― | 20.46% | ― | |
51 Neutral | HK$509.73M | 96.25 | 3.29% | ― | 60.75% | -63.30% | |
45 Neutral | HK$680.89M | -10.58 | -51.81% | ― | -20.65% | -616.18% |
Affluent Partners Holdings Corporate Events
Baijin Life Science Holdings Limited has entered into a strategic cooperation framework agreement with Shanghai Guhuan Medical Equipment Company Limited. This agreement aims to optimize Baijin’s market ecosystem for medical products and stabilize revenue streams by establishing proprietary sales channels. The agreement also involves the potential appointment of Mr. Liang Liang, an experienced professional in the medical cosmetic industry, to lead the Group’s medical business division.
Baijin Life Science Holdings Limited has successfully completed the issuance of 40 million new shares under a general mandate, raising gross proceeds of HK$19.2 million. The net proceeds of approximately HK$19.1 million will be allocated towards repaying borrowings and as general working capital, impacting the company’s financial structure and shareholder composition.
Baijin Life Science Holdings Limited announced its interim results for the six months ended 30 September 2025, reporting a revenue of HK$55,145,000, a decrease from the previous year’s HK$70,900,000. Despite the drop in revenue, the company achieved a profit of HK$2,517,000, a significant improvement from a loss of HK$1,901,000 in the same period last year, indicating a positive shift in financial performance.
Baijin Life Science Holdings Limited, a company listed on the Hong Kong Stock Exchange, has issued a positive profit alert. The company anticipates a net profit of approximately HK$2.5 million for the six months ending September 30, 2025, compared to a loss of HK$1.9 million in the same period of the previous year. This improvement is attributed to a gain from the change in fair value of a convertible bond, despite a decrease in gross profit. The results are preliminary and unaudited, with final figures expected to be released on November 27, 2025.
Baijin Life Science Holdings Limited, through its subsidiary Beijing Baijin Biotechnology, has entered into a strategic cooperation framework agreement with Youhuan Biopharmaceutical Technology. This collaboration aims to establish a leading circular RNA technology R&D platform to innovate in cell therapy, focusing on circRNA-based therapies for liver diseases, drug delivery technologies, and cell reprogramming for genetic diseases. The agreement is part of Baijin’s strategy to diversify its business and broaden its income streams, although it is still in the preliminary stages and subject to further agreements.
Baijin Life Science Holdings Limited, operating in the skincare industry, has announced a supplemental update to its 2025 Annual Report. The company recognized a goodwill impairment of approximately HK$20 million related to its acquisition of Tonnett Julis Holdings Limited. This impairment was due to the underperformance of Tonnett Group, particularly in its online sales strategy, which led to a shift towards partnering with larger distributors and the development of a flagship beauty club. The company believes this strategic pivot will benefit long-term growth but has temporarily decreased revenue.
Baijin Life Science Holdings Limited, listed on the Stock Exchange of Hong Kong, has announced a change in the board lot size of its shares from 32,000 to 8,000 shares, effective December 8, 2025. This adjustment aims to lower the investment threshold, enhance trading liquidity, and attract a broader base of investors, thereby benefiting both the company and its shareholders.
Baijin Life Science Holdings Limited, a company incorporated in the Cayman Islands, has announced an upcoming board meeting scheduled for November 27, 2025. The meeting will focus on approving the unaudited interim results for the six months ending September 30, 2025, and considering the payment of an interim dividend. This announcement indicates the company’s ongoing operational assessments and potential shareholder returns, reflecting its commitment to transparency and financial performance.
Baijin Life Science Holdings Limited has announced a supplemental update regarding the subscription of new shares under a general mandate. The company plans to allocate 60% of the net proceeds, approximately HK$11.5 million, towards repaying various borrowings by March 2026, and the remaining 40%, approximately HK$7.6 million, will be used as general working capital by September 2026. This strategic move aims to reduce interest expenses without impacting the company’s cash position, benefiting the company and its shareholders. New investors, including Mr. Liu Weidong, Ms. Zhou Suya, and Ms. Wang Huiqin, have subscribed to these shares, with no prior business relationships with the company.
Baijin Life Science Holdings Limited has announced the conversion of a convertible bond worth HK$31,500,000 into shares, leading to a change in its shareholding structure. This conversion will result in the cancellation of the bond, reducing the company’s liabilities and strengthening its balance sheet, thereby enhancing its financial position and enabling better resource allocation for future business development.
Baijin Life Science Holdings Limited, a company incorporated in the Cayman Islands, held its Annual General Meeting on 30 September 2025. All proposed resolutions, including the re-election of directors and the authorization for share issuance and repurchase, were unanimously approved by shareholders. The meeting saw full attendance from the board, highlighting the company’s commitment to governance and strategic direction.
Affluent Partners Holdings, under the name Baijin Life Science Holdings Limited, announced the subscription of 40,000,000 new shares at HK$0.48 per share, representing approximately 5.18% of its existing issued share capital. This move is part of a general mandate and involves three independent individual investors, with no inter-conditional agreements among them. The subscription aims to enhance the company’s capital base, although completion is subject to certain conditions.